Gaurav Narula

Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India

Nandana Das, Shripad Banavali, Sameer Bakhshi et al. · Trials · 2022 · 81 citations · Full text

Medicine, Hematology, Pediatrics +17

A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐10⁶and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients

Prashant Tembhare, Papagudi Ganesan Subramanian, Sitaram Ghogale et al. · Cytometry Part B Clinical Cytometry · 2019 · 77 citations · Full text

Medicine, Hematology, Oncology +15

Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000

Prashant Tembhare, Sitaram Ghogale, Nisha Ghatwai et al. · Cytometry Part B Clinical Cytometry · 2016 · 63 citations · Full text

Medicine, Hematology, Oncology +17

Cytogenetic Profile in 7209 Indian Patients with <i>de novo</i> Acute Leukemia: A Single Centre Study from India

P. S. Kadam Amare, H. K. Jain, Sharayu Kabre et al. · Journal of Cancer Therapy · 2016 · 48 citations · Full text

Life Sciences, Genetics, Hematology +16

Epidemiology of blood stream infections in pediatric patients at a Tertiary Care Cancer Centre

B Arora, Nisha Thacker, Naiura Vieira Pereira et al. · Indian Journal of Cancer · 2014 · 44 citations

Life Sciences, Microbiology, Pediatrics +16